A comparative study of regulatory prospects for drug-device combination products in major pharmaceutical jurisdictions

Abstract

In current scenario of innovative products, some of the products which hold a premier stand are those that combine, in some combination or others, elements of drugs, devices, and biologics. Drug-device combination products introduced a new change in medical product development, regulatory approval, and industrial interaction that provide valuable lessons for the development of new generations of medical products. These cutting-edge technologies have yielded the products to deliver drugs and biologics to specific targets within the body. In this paper, an introduction is given about combination products, their usefulness in the current drug delivery technologies, challenges in their regulation along with a brief history of these products, and overview of their regulatory status in major pharmaceutical jurisdictions. A brief review on regulatory path for their approval in various countries with special focus on drug device combinations along with the challenges faced by industries regarding their market approval is also given. For their market approval, the role and responsibilities of regulatory authority are addressed along with a brief description on review steps taken by Food and Drug Administration.

Whither Magnetic Hyperthermia? A Tentative Roadmap

“…At least in Europe, there is still a debate around whether a more specific regulatory framework-beyond the more recent regulation (EU) 2017/745 on medical devices repealing the 93/42/EEC and 90/385/EEC directives-is needed for nanomedical devices. The matter only worsens when considering the process in different pharmaceutical jurisdictions [13]. This uncertainty around well-defined pre-normative and regulatory frameworks is discouraging private investors and pharmaceutical companies from taking the initiative in leading new industrial projects or sponsoring the most promising current developments.…”

Pre-filled syringes in developed and developing region: An insight into Regulatory considerations

“…In India, combination products regulation is not clear; some products of this category are treated as drugs irrespective of the device component associated with it; e.g., drug eluting stent (15).…”